Emcure Pharma shares at record high! Stock soars 10% today, up 16% in 2 days: More rally ahead? Buy, sell or hold?
60-Word AI Digest
Emcure Pharmaceuticals shares hit a record high after rising 16% in two sessions, following strong Q2FY27 results. Profit increased 29% and revenue grew 24%. Jefferies and Kotak retained Buy ratings, citing growth prospects and setting target prices of ₹2,500 and ₹2,450.
Key Takeaways
- Emcure Pharmaceuticals shares hit a record high after rising 16% in two sessions, following strong Q2FY27 results.
- Profit increased 29% and revenue grew 24%.
- Jefferies and Kotak retained Buy ratings, citing growth prospects and setting target prices of ₹2,500 and ₹2,450.
Emcure Pharmaceuticals shares hit a record high after rising 16% in two sessions, following strong Q2FY27 results. Profit increased 29% and revenue grew 24%. Jefferies and Kotak retained Buy ratings, citing growth prospects and setting target prices of ₹2,500 and ₹2,450.
Original Publisher Attribution
This summary was curated from Livemint.